Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Eribulin
Drug ID BADD_D00798
Description Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors [A7439].
Indications and Usage For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
Marketing Status Prescription
ATC Code L01XX41
DrugBank ID DB08871
KEGG ID D08914
MeSH ID C490954
PubChem ID 11354606
TTD Drug ID D0XQ5X
NDC Product Code Not Available
Synonyms eribulin | E 7389 | E-7389 | ER-086526 | ER086526 | ER 086526 | ER-86526 | Halaven | NSC 707389 | NSC707389 | NSC-707389 | B 1793 | B-1793 | B 1939 | B-1939 | eribulin mesylate | eribulin monomethanesulfonate | eribulin mesilate | eribulin (as mesylate)
Chemical Information
Molecular Formula C40H59NO11
CAS Registry Number 253128-41-5
SMILES CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O 2)OC(C9OC)CC(CN)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lower limb fracture15.08.03.004; 12.04.01.0040.000533%Not Available
Demyelinating polyneuropathy17.09.04.003; 10.04.10.007--Not Available
Disease progression08.01.03.038--
Hepatobiliary disease09.01.08.003--Not Available
Respiratory tract infection22.07.07.001; 11.01.08.0170.000799%Not Available
Osteonecrosis of jaw24.04.05.005; 15.02.04.0100.003197%
Bone marrow failure01.03.03.0050.001066%
Cytopenia01.03.03.012--Not Available
Oral herpes11.05.02.005; 07.05.07.002--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Acute kidney injury20.01.03.016--
Drug-induced liver injury12.03.01.044; 09.01.07.023--Not Available
Pneumocystis jirovecii pneumonia22.07.08.009; 11.03.07.0050.000208%Not Available
Candida infection11.03.03.0210.000799%
Multiple organ dysfunction syndrome08.01.03.0570.000208%
Liver function test increased13.03.01.0440.000533%Not Available
Metastases to meninges17.02.10.012; 16.22.02.0030.000278%Not Available
Lymphangiosis carcinomatosa24.09.02.007; 16.22.02.009; 01.09.01.0270.000347%Not Available
Staphylococcus test positive13.08.01.0150.000533%Not Available
Spinal pain08.01.08.030; 17.10.01.020; 15.02.01.0080.000533%Not Available
Fulminant type 1 diabetes mellitus14.06.01.013; 05.06.01.0130.000533%Not Available
Pseudocirrhosis16.32.03.027; 09.01.04.0090.000139%Not Available
The 9th Page    First    Pre   9    Total 9 Pages